PE
IONS icon

Point72 Europe’s Ionis Pharmaceuticals IONS Stock Holding History

Point72 Europe’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$200K Buy
+3,051
New +$149K 0.01% 200

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Europe's IONS Position: Q3 2025 in Review

Point72 Europe opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2025: 3,051 shares worth $200K. The stake represents 0.01% of the portfolio and ranks #200 among its holdings.

435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

  • Point72 Europe held 3,051 shares of Ionis Pharmaceuticals worth $200K as of Q3 2025.
  • Ionis Pharmaceuticals was a new Point72 Europe position in Q3 2025.
  • Ionis Pharmaceuticals made up 0.01% of Point72 Europe's portfolio in Q3 2025, its #200 holding.
  • 435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.